CNSP News and Press, CNS Pharmaceuticals Inc. From 11/22/22

The National Brain Tumor Society anticipates that more than 13,000 Americans will receive a GBM diagnosis during 2022, accounting for 49.1% of all primary malignant brain tumors CNS announced the first patient in Europe has been enrolled and dosed in the global trial to evaluate Berubic...

Brain cancer affects an estimated 30 out of every 100,000 Americans. The debilitating disease currently has no cure but can often be managed by treatments such as radiation therapy, chemotherapy and surgery. However, these treatments aren’t always as effective as they could be due t...

CNS Pharmaceuticals CEO John Climaco participated in 5K run on November 5, to show support for brain tumor patients worldwide and help raise funds for research The company recently announced European clinical trial site activations for its potentially pivotal global trial evaluating Ber...

With the fields of machine learning and artificial intelligence (AI) evolving almost daily, experts in several industries are trying to figure out ways the technology can advance their specific sectors. Artificial intelligence can analyze an unfathomable number of data points in shockin...

CNS Pharmaceuticals (NASDAQ: CNSP) , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has announced its Q3 2022 financial report; the company also provided an update regarding its anti...

CNS Pharmaceuticals press release ( NASDAQ: CNSP ): Q3 Net loss of $3.4M As of September 30, 2022, the Company had cash of approximately $7.0 million and working capital of approximately $7.5 million. The Company's current expectation is that the cash on hand and the pro...

CNS Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update PR Newswire Significant progress advancing potentially pivotal trial evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (GBM) Quarter mar...

Even though there are several treatments that can be used to fight cancer and prolong a cancer patient’s life, the disease has no cure . For the longest time, scientists have been trying to find treatments that could completely eradicate cancer cells without the side effects typicall...

Brain cancer affects hundreds of thousands of people globally every year and, together with central nervous system tumors, is estimated to take more than 200,000 lives. Research has also found that brain tumors make up 85% to 90% of all central nervous system tumors. Physicians usually t...

CNS Pharmaceuticals (NASDAQ: CNSP) has been developing drug candidates for treating primary and metastatic brain and central nervous system cancer. “Berubicin, the company’s lead drug candidate, is a novel anthracycline in an ongoing international trail in glioblastoma ( ...